Old Skier
Tour Winner
Approx 1000 of the 4800 patients in the UK study and 420/4800 in the Brazil study over 56 years, and only half of them received the actual vaccine, so not a very convincing data set. The AZ data is quite frustrating. They have what os probably a pretty good vaccine, but some of the execution of the study has been clumsy, and what looks like several quite separate studies have been combined into one rather unwieldy data set. It looks a lot like studies designed by academics rather than pharma, which usually doesn't allow these elements to crop in.
The MHRA approach to it has been a bit odd. There is at least as much data to support a low dose-standard dose regimen as there is to support a delayed interval. The EMA and FDA have been very much less persuaded overall. I think if the EMA have decided to withhold it from older patients, that is fairly rational, and may also reflect their concern that the efficacy is a bit lighter than Pfizer/Moderna.
Still very keen to get their allocation of the vaccine though.